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Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious therapeutic problem
worldwide, and its frequency in most African countries has not been reported. This study
was aimed at determining the prevalence and antibiotic susceptibility patterns of MRSA
in eight large hospitals (>500 beds) in Africa and Malta, from 1996 to 1997. Susceptibility
to methicillin (oxacillin) and to other drugs was determined by E test (AB Biodisk, Solna,
Sweden) on a total of 1440 clinical isolates of S. aureus. Methicillin resistance was detected
in 213 (15%) of the 1440 isolates tested. The rate of MRSA was relatively high in Nigeria,
Kenya, and Cameroon (21–30%), and below 10% in Tunisia, Malta, and Algeria. All
MRSA isolates were sensitive to vancomycin, with MICs 4 mg/L. The isolates were also
highly sensitive to ciprofloxacin, except in Kenya, Morocco, and Tunisia, where relative
resistance to this drug was noted. Susceptibility to rifampin and fusidic acid seems to be
correlated with the clinical use of these compounds. Only 46% of 59 MRSA strains
analyzed were susceptible to rifampin, fusidic acid, and ciprofloxacin. The majority
(> 60%) of MRSA strains were multiresistant. There is a need to maintain surveillance
and control of MRSA infections in Africa.
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Methicillin-resistant Staphylococcus aureus (MRSA)
is a well-known etiologic agent of very serious
infections. The endemicity of this pathogen in many
countries today and the resistance of such isolates
to most antistaphylococcal antibiotics represent a
grave threat to public health.
In Africa, data on MRSA, particularly antibiotic
susceptibilities, are extremely limited [1–4]. The
objectives of this study were to determine the rates
and antibiotic susceptibility profiles of MRSA from
eight northern African countries and Malta over a
2-year period, 1996–97.
Routine clinical specimens were collected from
patients in large medical school-affiliated tertiary
and general hospitals (>500 beds) in eight African
countries and Malta between 1996 and 1997
(Table 1). The specimens comprised surgical sam-
ples (swabs and pus), ear, nose and throat samples,
urine, sputum, cerebrospinal fluid, aspirates and
blood cultures. All clinically significant staphylo-
coccal isolates from these specimens were identi-
fied by standard techniques [5]. Only one isolate of
S. aureus was considered per patient.
Methicillin resistance in S. aureus was detected
by testing, in each participating center, resistance
to oxacillin by E test (AB Biodisk, Solna, Sweden)
on Mueller–Hinton agar supplemented with 2%
NaCl and incubated at 37 8C for 24 h. The National
Committee for Clinical Laboratory Standards
(NCCLS) interpretive criteria for susceptibility
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categorization were used for the interpretation of
results, except for fusidic acid [6]. There are no
NCCLS E test fusidic acid quality control ranges
and interpretive standards. The AB Biodisk in-
house MIC range 0.06–0.25 mg/L quality control
organism S. aureus as contained in the package
insert supplement (AB Biodisk) was used as a
guide. An MIC above the control range was inter-
preted as resistant. Strains with oxacillin MICs
2 mg/L were considered susceptible, while strains
with MICs 4 mg/L were reported as resistant.
The percentage of MRSA was defined as the num-
ber of S. aureus isolates resistant to oxacillin
divided by the total number of S. aureus isolates
against which oxacillin was tested (100). The
susceptibilities of MRSA strains to some other
antistaphylococcal antibiotics (gentamicin, ery-
thromycin, rifampin, ciprofloxacin, fusidic acid,
co-trimoxazole, vancomycin) were also deter-
mined by E test, and the results were interpreted
as recommended [6]. b-Lactamase production was
tested in all MRSA isolates by use of chromogenic
cephalosporin disks (Nitrocefin, Oxoid) according
to the manufacturer’s instructions. S. aureus ATTC
29213 was tested along with the isolates.
During the study period, 1440 clinically signifi-
cant strains of S. aureus were isolated from the
various countries for analysis, of which 213
(14.8%) were resistant to methicillin. The rates of
MRSA in the various countries are depicted in
Table 2. Nigeria, Kenya and Cameroon recorded
the highest rates (21–30%), while Tunisia, Malta
and Algeria had the lowest (<10%). The majority
(42.5%) of MRSA strains analyzed were isolated
from surgical patients and from the medical ser-
vice. Seventy-one per cent of 176 isolates were
obtained from surgical swabs and pus, 14.2% from
blood, 8.5% from urine, and 6.3% from other speci-
mens.
All the 213 MRSA isolates produced b-lactamase
and were resistant to benzylpenicillin, but all were
sensitive to vancomycin, with MICs< 4 mg/L.
Fusidic acid (67.1%) was the most effective against
the isolates, followed by co-trimoxazole (60.2%),
rifampin (59.8%), and ciprofloxacin (54.9%). Gen-
tamicin and erythromycin had less than 50% effi-
cacy. However, very high MIC90s (>32 mg/L)
were obtained for all the aforementioned agents.
A closer analysis of the data from each country
showed high susceptibility to rifampin and cipro-
floxacin, except in Kenya and Tunisia, where rela-
tive resistance to these drugs was noted (Table 3).
MRSA strains with low oxacillin MICs (8 mg/
L) were highly susceptible to most of the antibio-
tics, particularly gentamicin and fusidic acid, but
with MIC90 values out of the susceptible range.
Except for fusidic acid and ciprofloxacin (58–78%),
percentages of drug susceptibility were below 45%
for MRSA strains with high oxacillin MICs
(16 mg/L) (Table 4).
Among 90 MRSA strains analyzed which were
tested against all the seven antibiotics used in the
study, no resistance was detected to any of the
drugs in six (6.7%) strains, while 17 (18.9%) were
resistant to only one antimicrobial agent. Seventy-
four per cent of the isolates were resistant to two or
more antibiotics. Forty-one of the 90 isolates were
sensitive to ciprofloxacin, rifampin, and fusidic
acid, while 13.3% were resistant to the latter agents.
In this study, a 14.8% rate of MRSA was
recorded from the nine hospitals. MRSA rates
of 21–30% were noted in Nigeria, Kenya, and
Table 1 Hospitals from which MRSA strains were isolated
in Sub-Saharan Africa and Malta, 1996–97
Country Hospital
Nigeria Lagos University Teaching Hospital,
Lagos
Kenya University of Nairobi Teaching
Hospital, Nairobi
Cameroon University of Yaounde Teaching
Hospital, Yaounde
Cote D’Ivoire Institut Pasteur, Abidjan
Morocco CHU Ibn, Rochd, Casablanca
Senegal CHU le Dantec, Dakar
Tunisia CHU Charles Nicolle, Tunis
Algeria Institut Pasteur, Algiers
Malta St Luke’s Hospital, Guardamangia
Table 2 Prevalence of MRSA in Sub-Saharan Africa and
Malta, 1996–97
Country
Total no. of
isolates tested
No. of MRSA
isolates
%
MRSA
Nigeria 142 42 29.6
Kenya 137 38 27.7
Cameroon 127 27 21.3
Cote D’Ivoire 155 26 16.8
Morocco 167 24 14.4
Senegal 168 21 12.5
Tunisia 186 15 8.1
Algeria 208 10 4.8
Malta 150 10 6.7
Total 1440 213 14.8
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Cameroon. In Morocco, Senegal and Cote D’Ivoire,
MRSA rates were between 10% and 20%. MRSA
rates were below 10% in Algeria, Tunisia and
Malta. Misuse and overuse of drugs, together with
lack of control measures in Nigeria, might have
been responsible for high MRSA rates. Spread of
resistant strains across the region, particularly to
neighboring West African countries, is also possi-
ble, since infection control practices were not in
place at the time of the study.
Generally, the rates obtained in this study are
lower than rates reported from previous studies in
the same hospitals in these countries [1,2,7,8]. In
Lagos, Nigeria, because of industrial unrest, only a
small number of S. aureus strains (37 as opposed to
142 in this study) were isolated and tested between
1994 and 1995, of which 21 (56.8%) were methi-
cillin resistant. Generally, fewer isolates were also
tested in the other hospitals in the previous years,
and this could explain the higher rates previously
reported. The MRSA rates obtained in this study
compare favorably with rates from Ethiopia [9,10]
and Somalia [11]. The Netherlands, Sweden and
Denmark have recorded MRSA rates of below 10%
[12,13]. MRSA rates between 10% and 20% have
been obtained from hospitals in Austria and Ger-
many [12]. MRSA rates ranging from 24% to 30%
are available from some hospitals in Switzerland,
Belgium and Spain, while slightly higher rates of
34% and 40% have been reported from France and
Italy, respectively [12]. The 14.8% MRSA rate
obtained from the nine large hospitals in this study
is discordant with a much higher prevalence rate
of 38.3% MRSA recorded in 1991 from large NNIS
teaching hospitals [14], but however, it is in accord
with a rate of 13.2% from England and Wales in
1995 [15].
All MRSA strains tested in this study were
susceptible to vancomycin. Fusidic acid, co-tri-
moxazole, rifampin and ciprofloxacin exhibited
moderate efficacy, while high rates of resistance
were obtained for gentamicin and erythromycin.
Similar findings have been reported elsewhere
[15–18]. The majority of the isolates were also
observed to have very high oxacillin MICs
(>16 mg/L) and were highly multiresistant. These
results were also in agreement with findings
outside this subregion [18]. Multiresistance is
Table 3 Antimicrobial susceptibility patterns of MRSA in various Sub-Saharan countries and Malta, 1996–97
Country
No. of isolates
analyzed
% Susceptibility of MRSA
GM EM RI CI FU TS VA
Nigeria 42 53.8 69.4 77.8 79.2 71.4 63.9 100
Kenya 38 15.4 23.1 23.1 55.9 42.9 7.7 100
Cameroon 27 48.2 44.4 88.9 86.4 – 48.2 100
Cote D’Ivoire 26 50 34.6 61.5 66.7 – 69.2 100
Morocco 21 – 42.9 – 23.8 47.6 61.9 100
Senegal 21 66.7 57.1 81 95.2 66.7 28.6 100
Tunisia 15 66.7 80 46.7 26.7 0 13.3 100
Malta 10 100 0 100 0 80 100 100
GM, gentamicin; EM, erythromycin; RI, rifampin; CI, ciprofloxacin; FU, fusidic acid; TS, trimethoprim–sulfamethoxazole;
VA, vancomycin; –, data not provided.
Table 4 Antimicrobial susceptibility patterns of MRSA by level of oxacillin resistance
Antibiotics
8 mg/L 16 mg/L
n % S MIC90 n % S MIC90
Gentamicin 25 80 64 64 26.6 >256
Erythromycin 30 56.7 >256 69 42 >256
Rifampin 36 94.4 0.5 69 39.1 >256
Ciprofloxacin 26 57.7 8 42 76.2 >32
Fusidic acid 31 77.4 32 70 57.1 >256
Trimethoprim–sulfamethoxazole 32 59.4 >32 48 39.6 >32
Vancomycin 31 100 3 69 100 3
n, no. of isolates analyzed; S, susceptible.
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reported to vary geographically [19]. In this study,
multiresistance was noted to be relatively higher in
Morocco, Kenya, Nigeria and Cameroon, with
more than 60% of the isolates exhibiting resistance
to at least three antibiotics.
Continuous surveillance of drug resistance in
MRSA in Sub-Saharan Africa and Malta is impera-
tive for the detection of emerging trends and the
development of appropriate therapeutic sche-
dules. Characterization of resistance mechanisms
may aid in tracing infection sources and the spread
of resistance traits. All these should culminate in
the eradication or the implementation of measures
to curtail the spread of MRSA.
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